Completed OBSERVATIONAL NCT06349655

The Real-world Clinical Study of Azvudine Tablets in the Treatment of COVID-19

Real-World Effectiveness and Safety of Oral Azvudine in Hospitalized Patients With COVID-19: A Multicenter, Retrospective, Cohort Study

Sponsor: Fengqiu County People's Hospital

Conditions Azvudine COVID-19

Interventions Azvudine Paxlovid

Updated 3 times since 2024 Last updated: Apr 4, 2024 Started: Dec 5, 2023 Primary completion: Jan 15, 2024 Completion: Mar 10, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06349655, this observational or N/A phase trial focuses on Azvudine and COVID-19 and remains completed. Sponsored by Fengqiu County People's Hospital, it has been updated 3 times since 2023, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
May 2024 — Jul 2024 [monthly]

Completed

First recorded

Dec 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fengqiu County People's Hospital
Guangshan County People's Hospital
Henan Provincial Chest Hospital
Luoyang Central Hospital
Nanyang Central Hospital
Shangqiu Municipal Hospital
The Affiliated Infectious Disease Hospital of Zhengzhou University
The Fifth People's Hospital of Anyang
The First Affiliated Hospital of Zhengzhou University

Data source: The First Affiliated Hospital of Zhengzhou University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zhengzhou, China